Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I¿IIIB): a phase II study

Abstract In a phase II study, we assessed the toxicity and efficacy of daily low-dose cisplatin (6 mg/m 2 ) and weekly vinorelbine (15 mg/m 2 ) with concurrent thoracic irradiation (60 Gy) for locally advanced non-metastasized non-small-cell lung cancer. The overall response rate was 65%, complete response 12% and the median overall survival was 64 weeks.